| |
|
Baseline |
Week 12 |
% change |
p value |
| All treated patients (n = 70) |
|
|
|
|
|
| Total cholesterol |
(mg/dL) |
228.8 ± 29.0 |
198.0 ± 26.1 |
-13.0 ± 10.1 |
<0.001 |
| Triglycerides |
(mg/dL) |
136.4 ± 110.3 |
119.1 ± 89.4 |
-5.0 ± 46.2 |
N.S. |
| TG ³ 150 mg/dL (n = 20) |
(mg/dL) |
249.7 ± 145.1 |
182.2 ± 100.6 |
-23.1 ± 28.9 |
0.005 |
| HDL cholesterol |
(mg/dL) |
54.1 ± 12.3 |
56.9 ± 12.6 |
5.9 ± 11.0 |
<0.001 |
| HDL cholesterol <40 mg/dL (n = 5) |
(mg/dL) |
32.8 ± 5.9 |
36.0 ± 6.0 |
10.5 ± 11.5 |
N.S. |
| LDL cholesterol |
(mg/dL) |
145.2 ± 21.3 |
115.6 ± 23.1 |
-19.7 ± 16.2 |
<0.001 |
| RLP cholesterol |
(mg/dL) |
5.8 ± 5.4 |
4.4 ± 2.8 |
-13.4 ± 29.9 |
<0.001 |
| RLP cholesterol ³5.2 (n = 23) |
(mg/dL) |
10.1 ± 7.7 |
6.1 ± 4.1 |
-34.4 ± 25.7 |
<0.001 |
| Cholesterol absorption marker/total cholesterol |
(mg/mg*103) |
7.1 ± 3.7 |
5.8 ± 2.1 |
-11.9 ± 26.4 |
<0.001 |
| Cholesterol synthesis marker/total cholesterol |
(mg/mg*103) |
1.8 ± 1.2 |
3.1 ± 1.7 |
90.8 ± 59.4 |
<0.001 |
| Fasting blood glucose |
(mg/dL) |
146.8 ± 49.2 |
147.6 ± 37.9 |
8.2 ± 39.0 |
N.S. |
| A1C |
(%) |
7.4 ± 0.8 |
7.5 ± 0.9 |
1.8 ± 6.2 |
N.S. |
| CPR |
(ng/mL) |
1.7 ± 1.1 |
1.7 ± 1.1 |
29.2 ± 106.6 |
N.S. |
| hs-CRP |
(ng/mL) |
1183.2 ± 1542.6 |
792.9 ± 866.6 |
-5.8 ± 57.0 |
0.003 |
| Monotherapy (n=57) |
|
|
|
|
|
| Total cholesterol |
(mg/dL) |
228.9 ±28.4 |
199.4 ± 25.3 |
-12.5 ± 9.5 |
<0.001 |
| Triglycerides |
(mg/dL) |
135.4 ± 110.5 |
117.0 ± 94.0 |
-7.5 ± 47.8 |
N.S. |
| TG ³ 150 mg/dL (n = 17) |
(mg/dL) |
241.9 ± 150.4 |
180.9 ± 107.3 |
-21.2 ± 30.8 |
0.02 |
| HDL cholesterol |
(mg/dL) |
54.2 ± 12.6 |
57.6 ± 13.2 |
6.8 ± 10.4 |
<0.001 |
| HDL cholesterol <40 mg/dL (n = 4) |
(mg/dL) |
32.8 ± 5.9 |
36.0 ± 6.0 |
10.5 ± 11.5 |
N.S. |
| LDL cholesterol |
(mg/dL) |
146.7 ± 21.2 |
115.5 ± 21.0 |
-20.7 ± 13.7 |
<0.001 |
| RLP cholesterol |
(mg/dL) |
5.8 ± 5.4 |
4.3 ± 3.0 |
-16.0 ± 30.0 |
0.001 |
| RLP cholesterol ³5.2 (n = 20) |
(mg/dL) |
9.7 ± 7.7 |
6.0 ± 4.4 |
-34.5 ± 26.1 |
0.002 |
| Cholesterol absorption marker/total cholesterol |
(mg/mg*103) |
6.7 ± 2.7 |
5.7 ± 1.8 |
-10.7 ± 25.1 |
<0.001 |
| Cholesterol synthesis marker/total cholesterol |
(mg/mg*103) |
1.9 ± 1.2 |
3.3 ± 1.6 |
93.6 ± 61.7 |
<0.001 |
| Fasting blood glucose |
(mg/dL) |
145.5 ± 47.0 |
149.3 ± 38.3 |
9.4 ± 38.8 |
N.S. |
| A1C |
(%) |
7.3 ± 0.8 |
7.4± 0.9 |
1.6 ± 8.6 |
N.S. |
| CPR |
(ng/mL) |
1.6 ± 1.1 |
1.7 ± 1.1 |
34.1 ± 110.7 |
N.S. |
| hs-CRP |
(ng/mL) |
1089.7 ± 1346.2 |
717.7 ± 705.0 |
-5.3 ± 56.9 |
0.011 |
| Combination (Ezetimibe + Statins) therapy (n=13) |
|
|
|
|
|
| Total cholesterol |
(mg/dL) |
222.0 ± 33.7 |
194.9 ± 29.6 |
-11.0 ± 16.5 |
0.029 |
| Triglycerides |
(mg/dL) |
137.5 ± 105.6 |
127.8 ± 58.3 |
6.7 ± 33.2 |
N.S. |
| TG³150 mg/dL (n=3) |
(mg/dL) |
293.7 ± 125.0 |
189.3 ± 62.7 |
-33.8 ± 12.3 |
N.S. |
| HDL cholesterol |
(mg/dL) |
53.7 ± 11.8 |
53.9 ± 9.4 |
2.0 ± 12.7 |
N.S. |
| HDL cholesterol <40 mg/dL (n=1) |
(mg/dL) |
32.8 ± 5.9 |
36.0 ± 6.0 |
10.5 ± 11.5 |
N.S. |
| LDL cholesterol |
(mg/dL) |
141.0 ± 20.2 |
114.2 ± 32.3 |
-15.5 ± 24.5 |
0.009 |
| RLP cholesterol |
(mg/dL) |
5.6 ± 5.3 |
4.5 ± 2.0 |
-2.5 ± 28.1 |
N.S. |
| RLP cholesterol ³5.2 (n=3) |
(mg/dL) |
12.5 ± 8.6 |
6.9 ± 2.1 |
-33.6 ± 27.4 |
N.S. |
| Cholesterol absorption marker/total cholesterol |
(mg/mg*103) |
9.1 ± 6.6 |
6.5 ± 3.0 |
-17.4 ± 32.4 |
<0.05 |
| Cholesterol synthesis marker/total cholesterol |
(mg/mg*103) |
1.3 ± 1.0 |
2.2 ± 1.8 |
78.8 ± 48.4 |
<0.05 |
| Fasting blood glucose |
(mg/dL) |
152.1 ± 60.0 |
140.3 ± 36.6 |
2.6 ± 40.9 |
N.S. |
| A1C |
(%) |
7.5 ± 0.8 |
7.6 ± 0.7 |
2.6 ± 5.4 |
N.S. |
| CPR |
(ng/mL) |
2.0 ± 1.3 |
1.7 ± 1.1 |
7.9 ± 87.1 |
N.S. |
| hs-CRP |
(ng/mL) |
1009.1 ± 1037.1 |
775.0 ± 692.8 |
-5.2 ± 62.1 |
N.S. |
A1C, hemoglobin A1C; CPR: C-peptide reactivity, hs-CRP: high-sensitivity C-reactive protein, HDL: high density lipoprotein, LDL: low density lipoprotein, RLP: remnant-like
lipoprotein. CPR (reference value): 1.2 to 2.0 ng/mL.